ALZAMEND NEURO, INC. Additional Paid in Capital
ALZAMEND NEURO, INC. (ALZN) had Additional Paid in Capital of $76.14 million as of 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-09-10
- 2026-07-31: Additional Paid in Capital $76.14M.
- 2026-04-30: Additional Paid in Capital $68.04M.
- 2026-01-31: Additional Paid in Capital $66.62M.
- 2025-10-31: Additional Paid in Capital $66.61M.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-07-31 | $76.14M 10-Q · filed 2026-09-10 | |
| 2026-04-30 | $68.04M 10-Q · filed 2026-09-10 | |
| 2026-01-31 | $66.62M 10-Q · filed 2026-03-11 | |
| 2025-10-31 | $66.61M 10-Q · filed 2025-12-09 | |
| 2025-07-31 | $66.58M 10-Q · filed 2025-09-10 | |
| 2025-04-30 | $62.50M 10-K · filed 2026-07-22 | |
| 2025-01-31 | $60.85M 10-Q · filed 2025-03-10 | |
| 2024-10-31 | $60.16M 10-Q · filed 2024-12-11 | |
| 2024-07-31 | $53.78M 10-Q · filed 2024-09-11 | |
| 2024-04-30 | $51.43M 10-K · filed 2025-07-22 | $51.43M 10-K · filed 2024-07-30 |
| 2024-01-31 | $48.97M 10-Q · filed 2024-03-25 | |
| 2023-10-31 | $62.70M 10-Q · filed 2023-12-15 | |
| 2023-07-31 | $62.36M 10-Q · filed 2023-09-13 | |
| 2023-04-30 | $62.00M 10-K · filed 2024-07-30 | $61.99M 10-K · filed 2023-07-27 |
| 2023-01-31 | $61.50M 10-Q · filed 2023-03-15 | |
| 2022-10-31 | $59.00M 10-Q · filed 2022-12-12 | |
| 2022-07-31 | $58.29M 10-Q · filed 2022-09-13 | |
| 2022-04-30 | $57.42M 10-K · filed 2023-07-27 | |
| 2022-01-31 | $52.16M 10-Q · filed 2022-03-15 | |
| 2021-10-31 | $50.65M 10-Q · filed 2021-12-13 | |
| 2021-07-31 | $49.37M 10-Q · filed 2021-09-13 | |
| 2021-04-30 | $33.72M 10-K · filed 2022-07-19 | |
| 2020-04-30 | $27.58M 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |